血浆内皮素,血管内皮生长因子水平在糖尿病肾病患者治疗前后变化的意义(2)
第1页 |
参见附件(2270KB,2页)。
参考文献
[1]刘力生.临床高血压学.第1版天津科学技术出版社,1999,112.
[2]董晓辉,陈潘藻.血管内皮生长因子的检测和临床意义.标记免疫分析与临床.
[3]Kohan DE.Endothelins in the kidney:Physiology and psthophysiology.Am J kidney,1993,22(4):493.
[4]王秋月,刘国宏,王春义,等.早期糖尿病肾病患者血浆内皮素,血纳素,血管紧张素Ⅱ的变化及意义.这中国实用内科学杂志,1998,18(12):722.
[5]Simon M,Rockl W,Hornig C,et al.Receptors of vascular endothelial growth factor/vascular permeability factor(vegf/vpf)in fetal and adult human kidney:localization and (125I)VEGF binding dites.J Am Soc Nephrol,1998,9(10):1032.
[6]Simon M,Grone HJ,Johren O,et,al.Expression of vascular endothelial growth factor and its receptiors in human renal ontogensis and in adult kidney.Am J Physiol,1995,268(1):7240.
[7]周智,扬义明,李艳,等.血浆血管生长因子及血管紧张素Ⅱ与糖尿病肾病的关系.中国病理生理杂志,2002,,18(5):551.
[8]Kim NH,Jung HH,ChaDR,et al.Expression of vascular endothelial growth factor in respose to high glucose in rat mesangial cells.J Endocrinol,2000,165(3):617.
[9]Cooper ME,Vranes D,Youssef S,et,al.Increased renal expression of vascular endothelial growth factor(VEGF)and VEGFR-2 inexperimental diabetes.Diabetes,1999,48(11):2229.
[10]卢小卓,方锦鎏.糖尿病肾病患者治疗前后AT-Ⅱ,VEGF,ET和ANP水平的变化.放射免疫学杂志,2003,16(4):200.
[11]Ame,miya T,Sasamura H,Mifune M,et,al.Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells.Kidney Int,1999,56(9):2055.
您现在查看是摘要介绍页,详见PDF附件(2270KB,2页)。